Proxyanalyst LogoProxyanalyst
CompaniesSpecial SituationsExplorerAbout
Terms and Conditions & Privacy PolicySitemap

BOSTON SCIENTIFIC CORP (BSX)

Sector: Health Care

ExecutivesDirectorsTrendsAnnual MeetingProxy Filings
    Home/Companies/BSX/Annual Meeting

2026 Annual Meeting Analysis

BOSTON SCIENTIFIC CORP · Meeting: April 30, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

10

Directors AGAINST

0

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Directors

10 FOR
✓ FOR
David C. Habiger

Joined the board in July 2024 (less than 24 months ago), so he is exempt from the TSR trigger under policy; brings relevant CEO and financial expertise with no overboarding or other policy concerns.

✓ FOR
Edward J. Ludwig

BSX's 3-year return of +28% outperforms the IHI (iShares US Medical Devices ETF) benchmark by +27.4 percentage points, well below the 65-percentage-point threshold needed to trigger a concern; Ludwig brings deep medtech governance expertise and no other flags apply.

✓ FOR
Michael F. Mahoney

As CEO and executive director, Mahoney is subject to the same TSR test as other directors; BSX's 3-year return of +28% vs. IHI's +0.6% yields a positive gap of +27.4 percentage points, far below the 65-percentage-point trigger threshold, so no TSR concern arises.

✓ FOR
Jessica L. Mega

Joined in June 2023 (approximately 33 months ago), which is more than 24 months but less than 3 years; the 3-year TSR trigger does not fire given BSX's strong outperformance of IHI, and her medical and technology expertise is clearly relevant.

✓ FOR
Susan E. Morano

Joined in June 2023 (approximately 33 months ago); TSR trigger does not apply given BSX's strong outperformance of IHI, and her deep medtech industry and finance background is directly relevant.

✓ FOR
Cheryl Pegus

Joined in May 2024 (less than 24 months ago), so she is exempt from the TSR trigger under policy; her healthcare CEO and clinical expertise are well-suited to BSX's business.

✓ FOR
Cathy R. Smith

Joined in February 2026 (well under 24 months), so she is exempt from the TSR trigger under policy; her CFO-level financial expertise and public company board experience are directly relevant.

✓ FOR
Christophe P. Weber

Joined in February 2026 (well under 24 months), so he is exempt from the TSR trigger under policy; his global pharmaceutical CEO experience adds relevant strategic oversight capability.

✓ FOR
David S. Wichmann

BSX's 3-year return of +28% outperforms IHI (iShares US Medical Devices ETF) by +27.4 percentage points, far below the 65-percentage-point threshold needed to trigger a concern; Wichmann brings strong healthcare CEO and financial expertise.

✓ FOR
Ellen M. Zane

BSX's 3-year return of +28% outperforms IHI (iShares US Medical Devices ETF) by +27.4 percentage points, well below the 65-percentage-point trigger threshold; Zane brings relevant healthcare and governance experience with no other policy flags.

All ten director nominees receive a FOR vote. BSX's 3-year price return of +28% outperforms the IHI (iShares US Medical Devices ETF) benchmark by +27.4 percentage points, which is well below the 65-percentage-point trigger threshold applicable to companies with strong positive TSR. Directors who joined within the past 24 months (Habiger, Pegus, Smith, Weber) are exempt from the TSR trigger entirely. No overboarding, independence, attendance, or familial-relationship concerns were identified for any nominee.

Say on Pay

✓ FOR

CEO

Michael F. Mahoney

Total Comp

$23,532,050

Prior Support

N/A

CEO total compensation of $23.5 million is within a reasonable range for the chief executive of a $93 billion large-cap medical device company with a strong 3-year track record. The pay structure is heavily weighted toward variable, performance-based compensation — at least 50% of total pay is in long-term equity and annual bonus tied to measurable financial goals (adjusted net sales, adjusted EPS, adjusted operating income margin) plus a relative total shareholder return program benchmarked against the S&P 500 Health Care Index, meeting the pay-mix quality standard. BSX's 3-year return of +28% significantly outperforms the IHI (iShares US Medical Devices ETF) by +27.4 percentage points, confirming that above-benchmark incentive pay is supported by strong shareholder returns, satisfying the pay-for-performance alignment check.

Auditor Ratification

✓ FOR

Auditor

Ernst & Young LLP

Tenure

N/A

Audit Fees

$17,995,000

Non-Audit Fees

$1,180,000

Non-audit fees (audit-related fees of $925,000 plus tax fees of $255,000 = $1,180,000) represent approximately 6.6% of audit fees ($17,995,000), well below the 50% threshold that would raise independence concerns. Auditor tenure is not explicitly disclosed in the proxy, so the tenure trigger cannot fire per policy. Ernst & Young is a Big 4 firm fully appropriate for a company of BSX's size and complexity. No material financial restatements were identified.

Stockholder Proposals

4 proposals submitted by shareholders

Proposal 5

Amend Our Certificate of Incorporation to Remove Supermajority Voting Provisions

✓ FOR
Filed by:Board of Directors (company-proposed charter amendment)OtherCharter Amendment
Prior-year support: 95% (A non-binding stockholder proposal requesting elimination of supermajority voting provisions received over 95% support at the 2025 annual meeting.)
Board recommends: FOR
⚑ 95% prior-year stockholder support⚑ governance improvement — removes 80% supermajority requirements⚑ direct board response to overwhelming shareholder mandate

This is a board-proposed charter amendment that directly responds to a stockholder proposal that received over 95% support at the 2025 annual meeting — one of the clearest possible signals that shareholders want this change. The amendment removes 80% supermajority voting requirements on key governance provisions (director removal, special meeting rules, bylaw amendments) and replaces them with simple majority votes, which is a straightforward pro-shareholder improvement. Supporting this proposal aligns with the policy's guidance to support governance changes that eliminate entrenchment mechanisms and improve shareholder rights.

Proposal 6

Amend Our Certificate of Incorporation to Provide for Exculpation of Certain Officers as Permitted by Delaware Law

✓ FOR
Filed by:Board of Directors (company-proposed charter amendment)OtherCharter Amendment
Board recommends: FOR
⚑ Delaware law change enables officer exculpation parity with directors⚑ limited scope — does not cover duty of loyalty breaches, bad faith, or self-dealing

Delaware law was changed in 2022 to allow companies to extend to certain officers the same protection from personal liability for honest mistakes that directors have long enjoyed. The proposed amendment is narrowly scoped — it does not protect against breaches of loyalty, bad faith, intentional misconduct, or transactions where an officer personally benefits improperly — and it only applies to direct claims, not derivative suits brought on behalf of the company. Extending this protection helps attract and retain qualified executives and aligns BSX's charter with standard Delaware corporate practice, without meaningfully weakening shareholder protections against misconduct.

Proposal 7

Amend Our Certificate of Incorporation and By-Laws to Permit Stockholders Holding 25% of Our Common Stock to Call a Special Meeting of Stockholders

✓ FOR
Filed by:Board of Directors (company-proposed charter amendment)OtherCharter Amendment
Board recommends: FOR
⚑ grants new shareholder right — currently no special meeting right exists⚑ 25% threshold is most common among S&P 500 companies with this right⚑ one-year holding requirement is standard

Currently, BSX shareholders have no ability to call a special meeting at all — that right belongs exclusively to the Board chair, president, or a majority of directors. This proposal creates a meaningful new shareholder right by allowing holders of at least 25% of shares (held continuously for one year) to request a special meeting, which is a genuine governance improvement over the current baseline of zero shareholder access. The 25% threshold is the most commonly adopted level among S&P 500 companies that provide this right (approximately 33% of such companies), and the policy guidance supports this type of structural governance improvement. Although a lower threshold (such as 10%) would be even more shareholder-friendly, moving from no right to a 25% right is a substantial improvement worth supporting.

Proposal 8

Give Shareholders the Ability to Call for a Special Shareholder Meeting

✗ AGAINST
Filed by:Not specified in the provided filing textOtherGovernance
Board recommends: AGAINST
⚑ company's own Proposal 7 fully addresses the subject matter of this stockholder proposal⚑ redundant with board-proposed Proposal 7 which grants special meeting rights at 25% threshold

The board has proactively proposed its own charter amendment (Proposal 7) to grant stockholders holding 25% of shares the right to call a special meeting, directly addressing the core ask of this stockholder proposal. Voting FOR this stockholder proposal would be redundant and could create conflicting or duplicative obligations, since the company's own proposal already remedies the absence of special meeting rights. The right course of action for shareholders who want this governance improvement is to support Proposal 7, which enacts the actual legal change, rather than this advisory stockholder request.

Overall Assessment

The 2026 Boston Scientific annual meeting features a clean ballot with no significant governance concerns. BSX's strong 3-year total shareholder return of +28% substantially outperforms the IHI (iShares US Medical Devices ETF) benchmark, supporting FOR votes across all ten director nominees and the Say on Pay proposal; three major board-proposed charter amendments meaningfully improve governance by eliminating supermajority requirements, creating new shareholder special meeting rights, and aligning officer liability protections with Delaware law, all warranting support, while the redundant stockholder special meeting proposal should be voted against given the company's own Proposal 7 already delivers the governance improvement.

Filing date: March 18, 2026·Policy v1.2·high confidence

Compensation Peer Group

14 companies disclosed in 2026 proxy filing

ABTAbbott Laboratories
AAgilent Technologies, Inc.
BAXBaxter International Inc.
BDXBecton, Dickinson and Company
DHRDanaher Corporation
EWEdwards Lifesciences Corporation
GEHCGE HealthCare Technologies Inc.
HOLXHologic, Inc.
ISRGIntuitive Surgical, Inc.
MDTMedtronic plc
DGXQuest Diagnostics Incorporated
SYKStryker Corporation
TMOThermo Fisher Scientific Inc.
ZBHZimmer Biomet Holdings Inc.